drugset / Trial / NCT06954116
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2028-12-31
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Tuvonralimab | Monoclonal antibody | 7.5 mg/kg | — |